<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Veliparib_Fabricates_You%27ve_Been_Assured_About</id>
		<title>Veliparib Fabricates You've Been Assured About - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Veliparib_Fabricates_You%27ve_Been_Assured_About"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Veliparib_Fabricates_You%27ve_Been_Assured_About&amp;action=history"/>
		<updated>2026-06-12T20:27:06Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=Veliparib_Fabricates_You%27ve_Been_Assured_About&amp;diff=165095&amp;oldid=prev</id>
		<title>Cell0linda: Створена сторінка: Blinding of study subjects and investigators was almost universally maintained by the use of identical placebo preparations. It should, however, be noted that m...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Veliparib_Fabricates_You%27ve_Been_Assured_About&amp;diff=165095&amp;oldid=prev"/>
				<updated>2017-04-14T08:12:36Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: Blinding of study subjects and investigators was almost universally maintained by the use of identical placebo preparations. It should, however, be noted that m...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Blinding of study subjects and investigators was almost universally maintained by the use of identical placebo preparations. It should, however, be noted that most investigators reported high levels of minor oral side-effects (tingling, itching and swelling beneath the tongue) in actively treated subjects, which could influence blinding. Full risk of bias assessments can be found in the characteristics of included studies�� table and Figs?2 and 3 of the full review. Symptom scores A total of 2333 active treatment (SLIT) and 2256 placebo patients were [http://www.selleckchem.com/products/ABT-888.html Veliparib nmr] included. The combined SMD following SLIT was ?0.49 (95% CI ?0.64 to ?0.34) favouring active treatment (P?[https://en.wikipedia.org/wiki/Lazabemide lazabemide] in three studies, with 286 participants in the SLIT and 304 in the placebo group. The combined SMD was 0.95 [http://www.selleckchem.com/products/DAPT-GSI-IX.html http://www.selleckchem.com/products/DAPT-GSI-IX.html] (95% CI 0.78 to 1.12, P?&lt;/div&gt;</summary>
		<author><name>Cell0linda</name></author>	</entry>

	</feed>